Robins/Rorer
Executive Summary
Next important date in the road to merger is Oct. 19. A hearing is scheduled in Richmond federal court on that day on Robins' motion for approval of a definitive merger plan. One hurdle was cleared on Oct. 1, with the encouragement of the court, when the Robins family execs worked out an agreement on indemnification with Rorer. The Robins execs reportedly had wanted the right to sell Rorer stock if necessary to pay for personal claims in the future. They settled for other protections in the agreement.
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.